AU2001284658A1 - Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists - Google Patents
Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonistsInfo
- Publication number
- AU2001284658A1 AU2001284658A1 AU2001284658A AU8465801A AU2001284658A1 AU 2001284658 A1 AU2001284658 A1 AU 2001284658A1 AU 2001284658 A AU2001284658 A AU 2001284658A AU 8465801 A AU8465801 A AU 8465801A AU 2001284658 A1 AU2001284658 A1 AU 2001284658A1
- Authority
- AU
- Australia
- Prior art keywords
- alkyl
- haloalkyl
- unsubstituted
- oxazolyl
- acid derivatives
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 101150014691 PPARA gene Proteins 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 229940083759 high-ceiling diuretics aryloxyacetic acid derivative Drugs 0.000 title 1
- -1 R2 is H Chemical group 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000001188 haloalkyl group Chemical group 0.000 abstract 3
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 125000004957 naphthylene group Chemical group 0.000 abstract 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Compounds represented by the following structural formula (I), and pharmaceutically acceptable salts, solvates and hydrates thereof, wherein R1 is an unsubstituted or substituted aryl, heteroaryl, cycloalkyl, aryl-alkyl, heteroaryl-alkyl or cycloalkyl-alkyl, R2 is H, alkyl or haloalkyl, the polymethylene chain (II), is saturated or may contain a carbon-carbon double bond, while n is 2, 3, 4, W is O or S, Y is an unsubstituted or substituted phenylene, naphthylene or 1, 2, 3, 4 tetrahydronaphthylene, R3 is H, alkyl or haloalkyl, R4 is H, alkyl, haloalkyl or a substituted or unsubstituted benzyl, are useful for modulating a preoxisome proliferator activated receptor, particularly in the treatment of diabetes mellitus.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22723300P | 2000-08-23 | 2000-08-23 | |
US60227233 | 2000-08-23 | ||
PCT/US2001/022615 WO2002018355A1 (en) | 2000-08-23 | 2001-08-23 | Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001284658A1 true AU2001284658A1 (en) | 2002-03-13 |
Family
ID=22852305
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001284658A Abandoned AU2001284658A1 (en) | 2000-08-23 | 2001-08-23 | Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists |
Country Status (9)
Country | Link |
---|---|
US (3) | US6982278B2 (en) |
EP (1) | EP1313715B1 (en) |
JP (1) | JP2004509084A (en) |
AT (1) | ATE368653T1 (en) |
AU (1) | AU2001284658A1 (en) |
CA (1) | CA2420178A1 (en) |
DE (1) | DE60129712T2 (en) |
ES (1) | ES2288982T3 (en) |
WO (1) | WO2002018355A1 (en) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002018355A1 (en) * | 2000-08-23 | 2002-03-07 | Eli Lilly And Company | Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists |
PT1313716E (en) | 2000-08-23 | 2007-07-11 | Lilly Co Eli | Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists |
US7176224B2 (en) | 2000-08-23 | 2007-02-13 | Eli Lilly And Company | Oxazolyl-aryloxyacetic acid derivatives and their use as PPAR agonists |
US7105551B2 (en) | 2000-12-20 | 2006-09-12 | Smithkline Beecham Corporation | Thiazole derivatives for treating PPAR related disorders |
CN1578659A (en) * | 2001-06-07 | 2005-02-09 | 伊莱利利公司 | Modulators of peroxisome proliferator activated receptors (ppar) |
AR036237A1 (en) | 2001-07-27 | 2004-08-25 | Bayer Corp | DERIVATIVES OF THE INDAN ACETIC ACID, INTERMEDIARIES, AND METHOD FOR THE PREPARATION, PHARMACEUTICAL COMPOSITION AND THE USE OF SUCH DERIVATIVES FOR THE MANUFACTURE OF A MEDICINAL PRODUCT |
US20110065129A1 (en) | 2001-07-27 | 2011-03-17 | Lowe Derek B | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation |
ITRM20020014A1 (en) * | 2002-01-15 | 2003-07-15 | Sigma Tau Ind Farmaceuti | DERIVATIVES OF A-PHENYLTHIOCARBOXYL AND A-PHYLYOXYCARBOXYL ACIDS USEFUL FOR THE TREATMENT OF DISEASES THAT RESPOND TO THE ACTIVATION OF |
JP2005529077A (en) | 2002-02-25 | 2005-09-29 | イーライ・リリー・アンド・カンパニー | Peroxisome proliferator-activated receptor modulator |
EP1480642B1 (en) | 2002-02-25 | 2008-11-26 | Eli Lilly And Company | Peroxisome proliferator activated receptor modulators |
US6833380B2 (en) | 2002-03-07 | 2004-12-21 | Warner-Lambert Company, Llc | Compounds that modulate PPAR activity and methods of preparation |
US6867224B2 (en) | 2002-03-07 | 2005-03-15 | Warner-Lambert Company | Compounds that modulate PPAR activity and methods of preparation |
UA79755C2 (en) * | 2002-04-16 | 2007-07-25 | Bayer Pharmaceuticals Corp | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation |
AU2003263814A1 (en) * | 2002-07-26 | 2004-02-16 | Bayer Pharmaceuticals Corporation | Indane, dihydrobenzofuran, and tetrahydronaphthalene carboxylic acid derivatives and their use as antidiabetics |
US7129268B2 (en) * | 2002-10-28 | 2006-10-31 | Novo Nordisk A/S | Peroxisome proliferator activated receptor-active arylene acetic acid derivatives |
AU2003276234B2 (en) * | 2002-11-08 | 2007-04-19 | F. Hoffmann-La Roche Ag | Substituted 4-alkoxyoxazol derivatives as PPAR agonists |
US7192970B2 (en) * | 2002-11-26 | 2007-03-20 | Chipscreen Biosciences, Ltd. | Noncyclic 1,3-dicarbonyl compounds as dual PPAR agonists with potent antihyperglycemic and antihyperlipidemic activity |
JP2006520755A (en) | 2003-02-14 | 2006-09-14 | イーライ リリー アンド カンパニー | Sulfonamide derivatives as PPAR modulators |
DE10308351A1 (en) | 2003-02-27 | 2004-11-25 | Aventis Pharma Deutschland Gmbh | 1,3-substituted cycloalkyl derivatives having acidic, usually heterocyclic groups, processes for their preparation and their use as medicaments |
DE10308355A1 (en) | 2003-02-27 | 2004-12-23 | Aventis Pharma Deutschland Gmbh | Aryl-cycloalkyl-substituted alkanoic acid derivatives, process for their preparation and their use as medicaments |
US7244763B2 (en) | 2003-04-17 | 2007-07-17 | Warner Lambert Company Llc | Compounds that modulate PPAR activity and methods of preparation |
CA2530983C (en) * | 2003-08-20 | 2012-09-25 | Eli Lilly And Company | Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide |
JP4767850B2 (en) * | 2003-08-20 | 2011-09-07 | エミスフィアー テクノロジーズ インコーポレイテッド | Compounds, methods and formulations for oral delivery of glucagon-like peptide (GLP) -1 compounds or melanocortin 4 receptor (MC4) agonist peptides |
SG148154A1 (en) * | 2003-11-05 | 2008-12-31 | Hoffmann La Roche | Benzannelated compounds as ppar activators |
EP2314576A1 (en) * | 2003-11-05 | 2011-04-27 | F.Hoffmann-La Roche Ag | Phenyl derivatives as PPAR agonists |
EP1745014B1 (en) * | 2004-05-05 | 2011-07-06 | High Point Pharmaceuticals, LLC | Novel compounds, their preparation and use |
US20110039841A1 (en) * | 2004-05-05 | 2011-02-17 | Novo Nordisk A/S | Novel compounds, their preparation and use |
JP2007284352A (en) * | 2004-08-05 | 2007-11-01 | Dai Ichi Seiyaku Co Ltd | Pyrazole derivative |
WO2006108491A1 (en) * | 2005-04-11 | 2006-10-19 | Dsm Fine Chemicals Austria Nfg Gmbh & Co Kg | Improved process for preparing oxazole nitriles |
WO2007071766A2 (en) | 2005-12-22 | 2007-06-28 | Transtech Pharma | Phenoxy acetic acids as ppar delta activators |
JO3598B1 (en) * | 2006-10-10 | 2020-07-05 | Infinity Discovery Inc | Boronic acids and esters as inhibitors of fatty acid amide hydrolase |
JP5637982B2 (en) * | 2008-04-09 | 2014-12-10 | インフィニティー ファーマシューティカルズ, インコーポレイテッド | Inhibitors of fatty acid amide hydrolase |
AU2010234445A1 (en) | 2009-04-07 | 2011-11-03 | Infinity Pharmaceuticals, Inc. | Inhibitors of fatty acid amide hydrolase |
EP2417115A4 (en) | 2009-04-07 | 2012-10-31 | Infinity Pharmaceuticals Inc | Inhibitors of fatty acid amide hydrolase |
KR101888026B1 (en) * | 2010-02-03 | 2018-08-13 | 인피니티 파마슈티컬스, 인코포레이티드 | Fatty acid amide hydrolase inhibitors |
US20130156720A1 (en) | 2010-08-27 | 2013-06-20 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
CN104230836B (en) * | 2014-09-29 | 2016-08-31 | 中国科学院成都生物研究所 | Phenyl azole compounds and the application in the medicine of preparation treatment cancer |
EP3913068B1 (en) | 2015-10-12 | 2023-08-02 | Advanced Cell Diagnostics, Inc. | In situ detection of nucleotide variants in high noise samples, and compositions and methods related thereto |
MX2023001001A (en) | 2020-07-22 | 2023-03-01 | Reneo Pharmaceuticals Inc | Crystalline ppar-delta agonist. |
WO2023147309A1 (en) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Use of ppar-delta agonists in the treatment of disease |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5089514A (en) * | 1990-06-14 | 1992-02-18 | Pfizer Inc. | 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents |
US5232945A (en) * | 1992-07-20 | 1993-08-03 | Pfizer Inc. | 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives |
US5902726A (en) * | 1994-12-23 | 1999-05-11 | Glaxo Wellcome Inc. | Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma |
JPH08325250A (en) * | 1995-05-31 | 1996-12-10 | Sumitomo Metal Ind Ltd | New substituted phenol derivative |
CA2245529A1 (en) | 1996-02-02 | 1997-08-07 | Soumya P. Sahoo | Antidiabetic agents |
GB9604242D0 (en) | 1996-02-28 | 1996-05-01 | Glaxo Wellcome Inc | Chemical compounds |
AU740444B2 (en) | 1996-08-19 | 2001-11-01 | Japan Tobacco Inc. | Propionic acid derivatives and use thereof |
AU3275999A (en) | 1998-03-10 | 1999-09-27 | Ono Pharmaceutical Co. Ltd. | Carboxylic acid derivatives and drugs containing the same as the active ingredient |
US6121300A (en) * | 1998-11-10 | 2000-09-19 | Wagle; Dilip R. | Reversing advanced glycosylation cross-links using heterocyclic-substituted thiazolium salts |
DK1206457T3 (en) * | 1999-08-27 | 2004-02-16 | Lilly Co Eli | Biaryl-oxa (thia) zole derivatives and their use as modulators PPAPs |
JP4316787B2 (en) * | 2000-01-11 | 2009-08-19 | 壽製薬株式会社 | An ether or amide derivative, a process for producing the same, and a therapeutic agent for diabetes containing the same, |
US7176224B2 (en) * | 2000-08-23 | 2007-02-13 | Eli Lilly And Company | Oxazolyl-aryloxyacetic acid derivatives and their use as PPAR agonists |
WO2002018355A1 (en) * | 2000-08-23 | 2002-03-07 | Eli Lilly And Company | Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists |
PT1313716E (en) * | 2000-08-23 | 2007-07-11 | Lilly Co Eli | Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists |
-
2001
- 2001-08-23 WO PCT/US2001/022615 patent/WO2002018355A1/en active IP Right Grant
- 2001-08-23 ES ES01963732T patent/ES2288982T3/en not_active Expired - Lifetime
- 2001-08-23 EP EP01963732A patent/EP1313715B1/en not_active Expired - Lifetime
- 2001-08-23 AU AU2001284658A patent/AU2001284658A1/en not_active Abandoned
- 2001-08-23 CA CA002420178A patent/CA2420178A1/en not_active Abandoned
- 2001-08-23 JP JP2002523473A patent/JP2004509084A/en not_active Revoked
- 2001-08-23 DE DE60129712T patent/DE60129712T2/en not_active Expired - Lifetime
- 2001-08-23 AT AT01963732T patent/ATE368653T1/en not_active IP Right Cessation
- 2001-08-23 US US10/343,474 patent/US6982278B2/en not_active Expired - Fee Related
-
2005
- 2005-07-14 US US11/181,640 patent/US7351728B2/en not_active Expired - Fee Related
-
2008
- 2008-01-11 US US11/972,668 patent/US20080146631A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2002018355A1 (en) | 2002-03-07 |
US6982278B2 (en) | 2006-01-03 |
JP2004509084A (en) | 2004-03-25 |
DE60129712D1 (en) | 2007-09-13 |
DE60129712T2 (en) | 2008-07-03 |
ES2288982T3 (en) | 2008-02-01 |
EP1313715A1 (en) | 2003-05-28 |
EP1313715B1 (en) | 2007-08-01 |
US20080146631A1 (en) | 2008-06-19 |
US7351728B2 (en) | 2008-04-01 |
CA2420178A1 (en) | 2002-03-07 |
US20040024034A1 (en) | 2004-02-05 |
ATE368653T1 (en) | 2007-08-15 |
US20050250825A1 (en) | 2005-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001284658A1 (en) | Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists | |
CY1107679T1 (en) | OXAZOLYL-ARYL PROPIONIC ACID PRODUCER AND USE THEM AS PPAR AGONORS | |
ZA200801885B (en) | Pyrrolopyridine derivatives and use of same as PPAR receptor modulators | |
EP1394154A4 (en) | Five-membered heterocyclic alkanoic acid derivative | |
NO883487L (en) | PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE HETEROCYCLIC COMPOUNDS. | |
DK1178982T3 (en) | Heterocyclic substituted aminoazacyclic compounds useful as agents for the central nervous system | |
WO2003048130A3 (en) | Peroxisome proliferator activated receptor agonists | |
EA200200470A1 (en) | NEW TIAZOLIDINDION DERIVATIVES AS ANTI-DIABETIC MEANS | |
NZ501785A (en) | 4-(3,4-dihydro-2-naphthylmethyl)- or 4-(2H-3-chromenylmethyl)-4,5-dihydro-1H-imidazole derivatives | |
CA2388314A1 (en) | Imidazole derivatives as phosphodiesterase vii inhibitors | |
IL145449A0 (en) | Processes for preparing pesticidal intermediates | |
AU4250200A (en) | Ppar-(gamma) agonists as agents for the treatment of type ii diabetes | |
EP1211253A4 (en) | Tricyclic dihydrobenzofuran derivatives, process for the preparation thereof and agents | |
ES2195500T3 (en) | DERIVATIVES OF 2-INDANOMETHANOL AND ITS USE BY PERFUMING INGREDIENTS. | |
WO1997029096A1 (en) | Micacocidin derivatives | |
JO2240B1 (en) | Process for the preparation of thiazolidinedione derivatives | |
CA2258960A1 (en) | A process for preparing naphthyridones and intermediates | |
WO2006021654A8 (en) | 4-arylmorpholin-3-one derivatives, preparation and therapeutic use thereof | |
AU2001225143A1 (en) | Tetramic acid derivatives for use in medicine and food technology | |
IT1312319B1 (en) | Preparation of citalopram used as antidepressant by dehydrating new oxazoline compound or thermally cleaving new thiazoline compound | |
IT1313587B1 (en) | Preparation of citalopram used as antidepressant by dehydrating new oxazoline compound or thermally cleaving new thiazoline compound | |
IT1302700B1 (en) | Preparation of citalopram used as antidepressant by dehydrating new oxazoline compound or thermally cleaving new thiazoline compound |